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Background: Tumour growth in colorectal cancer and other solid cancers is frequently supported by activating
mutations in the epidermal growth factor receptor (EGFR) signaling pathway (Patholog Res Int 2011:932932, 2011).
Treatment of metastatic colorectal cancer with targeted anti-EGFR therapeutics such as cetuximab extends survival
in only 25% of patients who test wild-type for KRAS, while the majority of patients prove resistant (J Clin Oncol
28(7):1254–1261, 2010).
Prediction of cetuximab responsiveness for KRAS wild-type colorectal cancers is currently not well defined, and
prognostic biomarkers would help tailor treatment to individual patients. Somatic mutation of the EGFR
signalling pathway is a prevalent mechanism of resistance to cetuximab (Nature 486(7404):532–536, 2012). If the
human genome harbours variants that influence susceptibility of the EGFR pathway to oncogenic mutation, such
variants could also be prognostic for cetuximab responsiveness.
Methods: We assessed whether patient genetic variants may associate with somatic mutation of the EGFR
signalling pathway. We combined tumour mutation data from the Cancer Genome Atlas with matched patient
genetic data, and tested for germline variants that associate with somatic mutation of the EGFR pathway
(including EGFR, KRAS, BRAF, PTEN and PIK3CA).
Results: Two single nucleotide polymorphisms (SNPs) located 90 kb upstream of the TERT oncogene associated
with somatic mutation of the EGFR pathway beyond the threshold of genome-wide significance: rs7736074
(P = 4.64 × 10-9) and rs4975596 (P = 5.69 × 10-9). We show that allelic variants of rs7736074 and rs4975596
modulate TERT expression levels in multiple cancer types, and exhibit preliminary prognostic value for
response to cetuximab.
Conclusions: We have identified two germline SNPs that associate with somatic mutation of the EGFR
pathway, and may be prognostic for cetuximab responsiveness. These variants could potentially contribute to
a panel of prognostic biomarkers for assessing whether metastatic colorectal cancer patients are likely to
derive benefit from cetuximab treatment. Genotyping of a large cohort of cetuximab-treated colorectal cancer
patients is called for to further clarify the association.* Correspondence: wormald@wehi.edu.au
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The growth of solid tumours is frequently supported by
aberrant expression of epidermal growth factor receptorFigure 1 Frequencies of somatic mutation in the EGFR pathway for diff
by mutation status for commonly mutated components of the EGFR pathway
considered mutant if a non-synonymous mutation was detected in one or mor
a 50% cutoff (dashed line). Cancer types with little or no evidence of EGFR path
were obtained from publicly available TCGA somatic mutation data (based on M
study due to reported strong environmental association between KRAS mutatio
p-values for association with somatic mutation status of the EGFR pathway. Can
Black points show p-values adjusted for population stratification using genomic
stratification by incorporation of the top 10 eigenvectors as covariates; grey poin
for association with somatic mutation status of the EGFR pathway. P-values wer
wide significance threshold (p = 8.78 × 10-8). Abbreviations: UCEC – uterine corp
thyroid carcinoma. COAD – colorectal adenocarcinoma. BRCA - breast invasive c
squamous cell carcinoma. LUAD – lung adenocarcinoma.(EGFR) or activating mutations in downstream signalling
components [1]. Monoclonal antibodies directed against
EGFR, including cetuximab and panitumumab, have shownerent solid tumour types. (A) TCGA tumour specimens were classified
, including EGFR, KRAS, BRAF, PIK3CA and PTEN. The EGFR pathway was
e of these factors. High and low mutation frequencies were determined by
way mutation are not shown. Somatic mutations for individual specimens
utSig analysis of whole-exome sequencing). LUAD was excluded from the
n status and smoke exposure [17]. (B) Quantile-quantile plot of GWAS SNP
cer types included in the analysis were: UCEC, SKCM, THCA and COAD.
inflation control; crosses show p-values adjusted for population
ts show non-adjusted p-values. (C) Manhattan plot of GWAS SNP p-values
e adjusted for genomic inflation. Grey dashed line indicates the genome-
us endometrial carcinoma. SKCM – skin cutaneous melanoma. THCA –
arcinoma. LUSC - lung squamous cell carcinoma. HNSC – head and neck
Table 1 Classification of TCGA patients according to EGFR
pathway mutation status
Number of patients
Cancer type EGFRpath + EGFRpath - Total
THCA 187 135 322
UCEC 206 42 248
SKCM 131 88 219
COAD/READ 128 96 224
All 652 361 1013
Abbreviations: THCA thyroid carcinoma, UCEC uterine corpus endometrial
carcinoma, SKCM skin cutaneous melanoma, COAD colorectal
adenocarcinoma, READ rectal adenocarcinoma, EGFRpath + somatic
mutation, EGFRpath - not mutated.
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chemotherapy for the treatment of colorectal cancer (CRC)
[2]. Despite providing new avenues of treatment for solid
cancers, effectiveness in the clinic has proved variable. 40%
of CRC cases harbor an activating mutation in KRAS
and derive no benefit from anti-EGFR therapy, while
only 13% of KRAS wild-type cases show an objective
response [3,4].
Regardless of their initial response, patients invariably
develop resistance to targeted EGFR therapy [3,5,6]. Re-
sistance is likely acquired by the emergence of mutations
within EGFR or the EGFR pathway, including KRAS,
BRAF, PIK3CA and PTEN. In KRAS wild-type CRC treated
with cetuximab, 6 out of 10 cases acquire activating muta-
tions in KRAS [3], and activating mutations in EGFR occur
in 2 out of 10 cases [6]. Likewise, half of all non-small cell
lung cancers treated with the EGFR inhibitors gefitinib or
erlotinib acquire a second mutation in exon 20 of EGFR
that confers resistance [5]. As response durations are typic-
ally measured in months, strategies to circumvent acquired
drug resistance are needed.
The personalization of cancer care aims to predict
effective therapy regimes according to the molecular
profiles of individual patients and their cancers [7].
Germline SNPs in two components of the EGFR sig-
nalling pathway, EGF and Cyclin D1, are associated with
overall survival in advanced CRC patients treated with
cetuximab monotherapy [8], and a SNP in LIFR showsTable 2 Top 5 SNPs identified by GWAS for EGFR
pathway status
Gene SNP ID Chromosome Positiona Region P valueb
SLC6A19 rs7736074 5 1189456 Upstream 4.64 ×10-9
SLC6A19 rs4975596 5 1189347 Upstream 5.69 ×10-9
ADAMTS6 rs715676 5 64450473 Intron 1.56 ×10-6
SLC6A19 rs6554634 5 1186121 Upstream 1.76 ×10-6
CECR3 rs4819993 22 17761425 Upstream 3.77 ×10-6
ahg19 coordinates.
bAdjusted for genomic inflation.association with response to cetuximab combination
therapy [9]. At the tumour level, somatic mutations in
EGFR, KRAS, BRAF, PTEN and PIK3CA are associated
with poor response to anti-EGFR therapy in CRC [2,10].
Even the majority of cancers initially negative for these
mutations fail to respond [2], probably because subpop-
ulations harboring drug-resistant mutations have been
selected [3]. The identification of germline biomarkers
that can predict whether a cancer is predisposed to acti-
vating mutations in the EGFR pathway would therefore
be an extremely useful therapeutic tool.
Methods
Data sets
Germline SNP data (Affymetrix SNP 6.0) for cancer pa-
tients were obtained from The Cancer Genome Atlas
(TCGA - level 2 Birdseed output) [11]. Matched somatic
mutation data and RNA seq data were obtained from
the TCGA exome sequencing pipeline and the TCGA
RNA seq pipeline respectively. Where multiple replicate
specimens were available from a single patient, one rep-
resentative specimen was selected at random. For as-
sociation analysis, patients were only included where
both germline SNP data and matched somatic mutation
data were available. For RNA-seq analysis, patients were
only included where both germline SNP data and matched
tumour RNA-seq data were available.
Germline SNP chip data for Korean colorectal cancer
patients and matched in vitro cetuximab response levels
[9] were obtained from the Gene Expresison Omnibus
[12] (GSE21228).
Genome wide association analysis
Genome wide SNP association was performed using the
GWASTools package for R [13]. Associations were tested
for using logistic regression under an additive model. For
quality control, SNPs exhibiting > 5% missing genotype
calls or non-Hardy-Weinberg equilibrium (p < 0.001) were
excluded. A relatively high minor allele frequency cutoff
of 10% was chosen due to the moderate number of
patients and the high frequency of the measured out-
come within the cancer patient population (meaning
that rare SNPs are unlikely to prove informative). Non-
autosomal SNPs were also excluded. In total, 580,710
out of 906,600 SNPs on the Affymetrix Human SNP 6.0
array were included in the final analysis. The genome-
wide significance p-value cutoff was calculated as 0.05/
(580,710 SNPs tested) = 8.61 × 10-8. Measurement of
the genomic inflation factor (λ) and adjustment of
P values for genomic inflation was performed using
the genomic control functionality of the METAL [14]
software package. Alternatively, eigenvectors as determined
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Figure 2 Patient genotype numbers and odds ratios for the top five SNPs associated with EGFR pathway status combined across four
cancer types (COAD, SKCM, THCA and UCEC). (A) Odds ratios for combined analysis. (B) Odds ratios for individual cancer types. Error bars
indicate 95% confidence intervals. +++P < 5 × 10-9; ++P < 5 × 10-7; +P < 5 × 10-6; ***P < 5 × 10-4; **P < 5 × 10-3; *P < 0.05.
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Raw counts from TCGA RNA-seq data were processed
using edgeR [16]. Briefly, counts were normalized within
samples, and negative binomial linear models applied,
allowing gene-level variance to be quantified using
Cox-Reid estimates of common and tagwise dispersions.
Differential expression was then tested for using a general-
ized linear model likelihood ratio test.
Results
Genetic association with EGFR pathway status in cancer
We sought to determine whether a patient’s germline
genetic profile influences susceptibility to mutation in
EGFR or downstream signaling components. To approach
this problem, we made use of The Cancer Genome Atlas
(TCGA) [11] project which collects both somatic muta-
tion data for patient tumours, as well as patients’ germline
genetic profiles. Individual cancer types within TCGA
comprise too few patients to attempt large scale association
analysis, however as somatic mutation of the EGFR path-
way is a hallmark of multiple types of solid cancer types, we
sought to maximize the power of our study by combining
patients across multiple cancer types that exhibit high fre-
quency of mutation in the EGFR pathway. We note this
increase in patient numbers comes at the expense ofpotentially losing signals specific to only single cancer
types.
First, somatic mutation frequencies for commonly mu-
tated components of the EGFR pathway (EGFR, KRAS,
BRAF, PIK3CA and PTEN) were assessed in multiple
solid cancer types (Figure 1A). Cancer types with moder-
ate to high frequencies of non-synonymous mutations in
the EGFR pathway (> 50%; Figure 1A) were combined for
subsequent analysis: uterine corpus endometrial carcinoma
(UCEC), skin cutaneous melanoma (SKCM), thyroid car-
cinoma (THCA) and colorectal adenocarcinoma (COAD).
As each of these cancer types exhibits dependency on
components of the EGFR pathway at similar frequencies
(Figure 1A), we anticipated that through combining them
we might uncover a common genetic predisposition.
Next, a genome-wide association study (GWAS) was
performed to measure germline genetic association with
somatic mutation of the EGFR pathway. Combining cases
of UCEC, SKCM, THCA and COAD yielded a total of
1,013 patients (Table 1). From 569,429 SNPs across 1,013
germline samples, a low genomic inflation factor of 1.026
was measured, suggesting a minimal level of population
stratification (Figure 1B).
Two SNPs were detected beyond the genome-wide sig-
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Figure 3 Relative TERT mRNA abundance between genotypes
in COAD, SKCM, THCA, UCEC, and two types of NSCLC: LUAD
and LUSC. (A) rs7736074: G/G (white bars), G/C (grey bars), C/C
(black bars). (B) rs4975596: C/C (white bars), C/T (grey bars), T/T (black
bars). RNAseq data was obtained for TCGA tumour specimens
corresponding to patients whose germline SNP profiles were analysed
in Figure 1. Significant differences in mRNA abundance between
genotypes were calculated using edgeR [16] (see Methods). Error bars
show standard error of the mean, and were derived from the edgeR
dispersion metric. ***P < 5 × 10-4; **P < 5 × 10-3; *P < 0.05.
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These SNPs, located on the short arm of chromosome
5 and separated by 109 bp, show a high degree of linkage
disequilibrium, with R2 = 1.0 for individuals of northern-
European ancestry, and R2 = 0.935 for individuals ofChinese or Japanese ancestry [18]. The close linkage be-
tween rs7736074 and rs4975596 provide important val-
idation that the observed association is not a technical
artifact of the SNP genotyping platform.
An additional quality control measure, principle com-
ponent analysis, indicated that mutation status of the
EGFR pathway is not simply driven by population struc-
ture (Additional file 1: Figure S1). Furthermore, different
approaches of accounting for population structure did
not dramatically alter the p-values for rs7736074 and
rs4975596 (Figure 1B and Additional file 1: Figure S2).
At the probe level, genotype intensity groups are gener-
ally well defined (Additional file 1: Figure S3), however
we identified some samples with genotype call p-values
above 0.05 (4% for rs7736074, 7% for rs4975596), indicat-
ing lower confidence calls (Additional file 1: Figure S4).
Both SNPs remain beyond genome-wide significance with
these lower-confidence calls excluded from the analysis
(rs7736074: 9.46×10-9; rs4975596: 2.67 × 10-8).
Rs7736074 and rs4975596 are located approximately
12 kb upstream of SLC6A19, and 90 kb downstream of
the gene encoding telomerase reverse transcriptase (TERT).
Genetic variants near TERT are strongly associated with
predisposition to eight or more different cancer types [19],
suggesting a potential mechanism by which rs7736074
and rs4975596 could influence the oncogenic potential
of the EGFR signaling pathway through modulation of
TERT activity.
We also identified three additional SNPs that appear
suggestive based on visual inspection of the quantile
distribution for SNP P values, despite failing to achieve
genome-wide significance (Figure 1B). Of the top five
SNPs identified, four were located on chromosome 5,
and one on chromosome 22 (Table 2). Uniform effect sizes
were observed both for the combined analysis (Figure 2A)
and for individual cancer types (Figure 2B).
SNPs rs7736074 and rs4975596 associate with TERT
expression levels
The 15p5.33 locus, harboring SLC6A19 and TERT, is
of particular importance in non-small cell lung cancer
(NSCLC), where copy number amplification of the region
is found in 78% of cases [20]. As SNPs at this locus could
potentially influence oncogenesis by modulating TERT ex-
pression, we examined whether rs7736074 and rs4975596
associate with TERT expression levels in COAD, SKCM,
THCA, UCEC, as well as for two subtypes of NSCLC
(squamous cell or adenocarcinoma). We detected modest
significant differences (P < 0.05) in TERT expression be-
tween genotypes for THCA and UCEC, and larger signifi-
cant differences for the two NSCLC subtypes (P < 0.005
and P < 0.0005; Figure 3A and 3B). We observed similar
trends for COAD and SKCM, however these effects were
not significant. We hypothesize that the observed
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differing degrees of cellular heterogeneity, or to differ-
ing degrees of TERT sensitivity.
TERT expression profiles for rs7736074 and rs4975596
were nearly identical, reflecting the high degree of link-
age between these polymorphisms (Figure 3A and 3B).
The relationship between genotype and TERT expression
was generally consistent between cancer tumour types
(Figure 3A and 3B). Heterozygotes typically exhibited
heightened expression levels, suggesting a complex rela-
tionship between genotype and other factors (such as
copy-number or methylation) in determining TERT ex-
pression levels. In particular, the substantial differential
expression of TERT between genotypes in the two NSCLC
subtypes suggests that genotype could play a role in deter-
mining copy-number amplification of TERT.SNPs rs7736074 and rs4975596 associate with in vitro
tumor sensitivity to cetuximab
Understanding how germline genetic variation influences
the EGFR pathway in cancer may aid in prediction of
patient responses to targeted therapeutics. To test this
hypothesis, and verify our GWAS findings in an inde-
pendent population, we examined the association of SNPs
from Table 2 with in vitro tumor response to cetuximab
(Erbitux) using publicly available SNP data for 118 Korean
colorectal cancer patients [9] (GEO series GSE21228;
association with Erbitux response in the absence of
chemotherapy). The profile of odds ratios for in vitro
response to cetuximab (as measured by tumor cell
viability) was concordant with the odds ratios observed
for somatic mutation of the EGFR pathway (Figure 4;
compare with Figure 2B). Significant association with
in vitro cetuximab response was observed for SLC6A19
SNPs rs7736074 and rs4975596 (P = 0.003 and 0.002
respectively). This finding supports our hypothesis









rs4819993 10 34 41
rs6554634 65 17 5
rs715676 21 45 21
rs4975596 14 34 39
rs7736074 37 36 14
Figure 4 SNPs rs4975596 and rs7736074 associate with in vitro tumo
calculated for in vitro response to cetuximab, using the same panel of SNP
Korean colorectal cancer patients from the GEO database (accession GEO 2may serve as informative biomarkers for predicting ce-
tuximab response.
Discussion
At the molecular level, most human cancers can be classi-
fied into one or more subtypes of disease. The germline
genetic profile of a patient can influence predisposition
to specific cancer subtypes; in breast cancer, for example,
FGFR2 variants are strongly associated with ER-positive
but not ER-negative breast cancer [21]. In CRC, out-
growth of tumour subpopulations harboring mutations
in components of the EGFR pathway is strongly associ-
ated with acquired resistance to cetuximab [4]. Cancer
heterogeneity may confound the detection of such mu-
tations by biopsy, or they may arise during the course of
treatment. This study aimed to determine whether spe-
cific germline genetic factors may predispose patients
to the acquisition of mutations in the EGFR pathway,
and thus to cetuximab resistance. By including multiple
components of the EGFR pathway in our association
analysis, we aimed to isolate genetic variants that influ-
ence the EGFR pathway as a whole, as we reasoned
these would likely be most informative.
We identified germline SNPs at 15p5.33 that associate
with somatic mutation of the EGFR signaling pathway
in TCGA patients. In an attempt to further validate this
finding, we examined association of the SNPs with
in vitro resistance to cetuximab (which likely reflects to
some extent the mutation status of the EGFR pathway)
in an independent cohort of CRC patients, and found
them to be significant.
15p5.33 is a hotspot of genetic predisposition for mul-
tiple cancer types, probably because oncogenesis and cell
immortalization are closely linked with the telomere
maintenance activities of TERT [19]. We postulate that
the SNPs we identified may be in linkage with a regu-
latory element that modulates TERT expression. Con-












ur sensitivity to cetuximab. Patient genotypes and odds ratios were
s as in Figure 2. Genotype and response data were obtained for 118
1228) as described previously [9].
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rs4975596/rs7736074 in multiple cancer types. Associ-
ation was strongest in squamous-cell carcinomas and
adenocarcinomas of the lung, where the 15p5.33/TERT
locus is amplified at particularly high frequency [20].
The other cancer types we examined exhibited similar
regulatory trends albeit at decreased magnitude and
significance, possibly due to differences in TERT de-
pendence, tumour heterogeneity, or the action of alter-
native regulatory pathways at rs4975596/rs7736074 in
lung cancer.
Numerous studies have reported regulation of TERT
by EGFR-responsive factors including Wnt/B-catenin
[22], Myc [23], and NFkB [24]. Further evidence for a
regulatory link between EGFR and TERT was reported
recently in malignant glioma, where 92% of cases harboring
EGFR amplification were accompanied by a mutation in
the TERT promoter [25]. Polymorphisms that disrupt a
regulatory element linking EGFR signaling to TERT expres-
sion would thus impede the oncogenic potential of the
EGFR pathway, and may reduce the likelihood of the path-
way succumbing to somatic mutation.
Conclusion
The EGFR pathway induces pro-proliferative and anti-
apoptotic signals, and constitutes a convenient target for
somatic mutation in cancer. The occurrence of such a
mutation can impede the effectiveness of anti-EGFR ther-
apeutics such as cetuximab. We used TCGA patient data
to assess whether genetic variants may predispose to som-
atic mutation of the EGFR pathway. We identified two
SNPs located 90 kb upstream of TERT, rs7736074 and
rs4975596, that associate with EGFR pathway mutation
(P < = 5.69 × 10-9). We found the same two SNPs were
also predictive of in vitro cetuximab resistance using pub-
licly available genetic data from Korean colorectal cancer
patients [9]. Our results suggest that genetic variants may
predispose to somatic mutation of the EGFR pathway, and
consequently to resistance with anti-EGFR therapeutics.
Larger studies are called for to further characterize the
contribution of patient genetic variation to anti-EGFR
therapeutic resistance.
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